Pregled bibliografske jedinice broj: 350168
Patgogenesis and management issues for non-alcocholic fatty liver disease
Patgogenesis and management issues for non-alcocholic fatty liver disease // World Journal of Gastroenterology, 13 (2007), 34; 4539-4550 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 350168 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Patgogenesis and management issues for non-alcocholic fatty liver disease
Autori
Duvnjak, Marko ; Lerotić, Ivan ; Baršić, Neven ; Tomašić, Vedran ; Virović-Jukić, Lucija, Velagić, Vedran
Izvornik
World Journal of Gastroenterology (1007-9327) 13
(2007), 34;
4539-4550
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Non-alcoholic fatty liver disease; Metabolic syndrome; Obesity; Insulin resistance; Liver fibrosis; NAFLD treatment
Sažetak
Non-alcoholic fatty liver disease, Metabolic syndrome, Obesity, Insulin resistance, Liver fibrosis, NAFLD treatment Sažetak: Nonalcoholic fatty liver disease (NAFLD) has, although it is a very common disorder, only relatively recently gained broader interest among physicians and scientists. Fatty liver has been documented in up to 10 to 15 percent of normal individuals and 70 to 80 percent of obese individuals. Although the pathophysiology of NAFLD is still subject to intensive research, several players and mechanisms have been suggested based on the substantial evidence. Excessive hepatocyte triglyceride accumulation resulting from insulin resistance is the first step in the proposed 'two hit' model of the pathogenesis of NAFLD. Oxidative stress resulting from mitochondrial fatty acids oxidation, NF-kappaB-dependent inflammatory cytokine expression and adipocytokines are all considered to be the potential factors causing second hits which lead to hepatocyte injury, inflammation and fibrosis. Although it was initially believed that NAFLD is a completely benign disorder, histologic follow-up studies have showed that fibrosis progression occurs in about a third of patients. A small number of patients with NAFLD eventually ends up with end-stage liver disease and even hepatocellular carcinoma. Although liver biopsy is currently the only way to confirm the NAFLD diagnosis and distinguish between fatty liver alone and NASH, no guidelines or firm recommendations can still be made as for when and in whom it is necessary. Increased physical activity, gradual weight reduction and in selected cases bariatric surgery remain the mainstay of NAFLD therapy. Studies with pharmacologic agents are showing promising results, but available data are still insufficient to make specific recommendations ; their use therefore remains highly individual.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
045-1080230-0516 - Metabolički sindrom u šećernoj bolesti tipa 1 (Smirčić-Duvnjak, Lea, MZOS ) ( CroRIS)
108-1080230-0143 - Istraživanje nealkoholne masne bolesti jetre u sklopu metaboličkog sindroma (Duvnjak, Marko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- CAB Abstracts
- EMBASE (Excerpta Medica)